<DOC>
	<DOCNO>NCT02728050</DOCNO>
	<brief_summary>This phase I/II trial study side effect best dose filgrastim ( granulocyte colony-stimulating factor [ G-CSF ] ) , cladribine , cytarabine , mitoxantrone hydrochloride , give together sorafenib tosylate see well work treat patient newly-diagnosed acute myeloid leukemia high-risk myelodysplastic syndrome ( likely aggressive ) . Drugs use chemotherapy , filgrastim , cladribine , cytarabine , mitoxantrone hydrochloride work different way stop growth cancer cell , either kill cell , stop dividing , stop spread . Sorafenib tosylate may stop growth cancer cell block enzymes need cell growth . Giving filgrastim , cladribine , cytarabine , mitoxantrone hydrochloride together sorafenib tosylate may kill cancer cell .</brief_summary>
	<brief_title>Filgrastim , Cladribine , Cytarabine , Mitoxantrone With Sorafenib Tosylate Treating Patients With Newly-Diagnosed , Acute Myeloid Leukemia High-Risk Myelodysplastic Syndrome</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To assess maximum tolerate dose ( MTD ) sorafenib ( sorafenib tosylate ) use combination dose-intensified mitoxantrone ( mitoxantrone hydrochloride ) part G-CSF , cladribine , cytarabine mitoxantrone hydrochloride ( G-CLAM ) regimen adults newly-diagnosed acute myeloid leukemia ( AML ) /high-risk myelodysplastic syndrome ( MDS ) . ( Phase 1 ) II . To determine addition sorafenib G-CLAM improves rate minimal residual disease negative ( MRDneg ) complete response ( CR ) compare center 's historical control G-CLAM alone adults newly-diagnosed AML/high-risk MDS . ( Phase 2 ) SECONDARY OBJECTIVES : I . To estimate rate CR , overall response rate ( ORR ) , overall survival ( OS ) , event-free survival ( EFS ) , relapse-free survival ( RFS ) addition sorafenib G-CLAM patient newly-diagnosed AML/high-risk MDS . II . To describe toxicity profile safety ( rate adverse event ) sorafenib combination G-CLAM . III . To assess feasibility incorporate quality life ( QOL ) , cost healthcare resource utilization endpoint phase 1/2 clinical trial newly diagnose AML . IV . To investigate , within limit phase 1/2 trial , impact study treatment response quality life , cost , healthcare resource utilization patient AML undergo intensive chemotherapy . OUTLINE : This phase I , dose-escalation study mitoxantrone sorafenib tosylate follow phase II study . INDUCTION : Patients receive mitoxantrone hydrochloride intravenously ( IV ) 60 minute day 1-3 sorafenib tosylate orally ( PO ) twice daily ( BID ) day 10-19 absence disease progression unacceptable toxicity . Patients also receive filgrastim subcutaneously ( SC ) daily ( QD ) day 0-5 , cladribine IV QD 2 hour day 1-5 , cytarabine IV QD 2 hour day 1-5 absence disease progression unacceptable toxicity . Patients achieve partial remission ( include MRD positive [ po ] CR , CR incomplete platelet recovery [ CRp ] , CR incomplete count recovery [ CRi ] ) persistent AML may receive 2 course induction therapy per discretion treat physician . POST-REMISSION : Patients receive sorafenib tosylate PO BID day 8-27 3 day prior next course treatment , whichever occur first . Patients also receive filgrastim subcutaneously SC QD day 0-5 , cladribine IV QD 2 hour day 1-5 , cytarabine IV QD 2 hour day 1-5 absence disease progression unacceptable toxicity . Patients achieve MRDneg CR may receive 4 course post-remission therapy . Patients achieve disease response ( MRDpos CR , CRi/CRp , persistent disease ) may receive two induction course 1 course post-remission therapy mitoxantrone hydrochloride omit course 3 . If enter MRDneg CR , proceed total 4 course post-remission therapy . MAINTENANCE THERAPY : Patients achieve MRDneg CR may receive maintenance therapy sorafenib tosylate PO BID 1 year . After completion study treatment , patient follow every 3 month 5 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Leukemia , Biphenotypic , Acute</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Cladribine</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Newly diagnose disease either diagnosis `` highrisk '' MDS &gt; = 10 % blast marrow blood ) , highrisk myeloproliferative neoplasm ( MPN ; &gt; = 10 % blast blood bone marrow ) , AML acute promyelocytic leukemia ( APL ) ( 15 ; 17 ) ( q22 ; q12 ) variant accord 2008 World Health Organization ( WHO ) classification ; patient biphenotypic AML eligible ; `` highrisk '' MDS MPN natural history much closer AML low risk MDS MPN respond similarly `` AMLtype '' therapy Outside diagnostic material acceptable long peripheral blood and/or bone marrow slide review study institution appropriate clinical staff ; flow cytometric analysis peripheral blood and/or bone marrow perform accord institutional practice guideline Treatmentrelated mortality ( TRM ) score = &lt; 13.1 calculate simplify model The use hydroxyurea prior study registration allow ; patient symptoms/signs hyperleukocytosis white blood cell ( WBC ) &gt; 100,000/uL treated leukapheresis may receive 2 dos cytarabine ( 500 mg/m^2/dose ) prior study day 0 enrollment Bilirubin = &lt; 2 time institutional upper limit normal unless elevation thought due hepatic infiltration AML , Gilbert 's syndrome , hemolysis ( assess within 10 day prior study day 0 ) Serum creatinine = &lt; 2.0 mg/dL ( assess within 10 day prior study day 0 ) Left ventricular ejection fraction &gt; = 45 % , assess within 3 month prior study day 0 , e.g . multi gate acquisition scan ( MUGA ) scan echocardiography , appropriate diagnostic modality clinical evidence congestive heart failure Women childbearing potential men must agree use adequate contraception begin sign consent least 4 week last dose study drug Provide write informed consent ( legal representative ) Myeloid blast crisis chronic myeloid leukemia ( CML ) , unless patient consider candidate tyrosine kinase inhibitor treatment Concomitant illness associate likely survival &lt; 1 year Active systemic fungal , bacterial , viral , infection , unless disease treatment antimicrobial and/or control stable ( e.g . specific , effective therapy available/feasible desire [ e.g . chronic viral hepatitis , human immunodeficiency virus ( HIV ) ] ) ; patient need clinically stable define afebrile hemodynamically stable 2448 hour prior study day 0 , unless fever think secondary underlie hematologic disease Active clinically significant ( symptomatic ) cardiac disease , include active coronary artery disease , cardiac arrhythmia require antiarrhythmic therapy beta blocker digoxin within last 3 month , unstable angina ( anginal symptom rest ) , newonset angina within 3 month randomization , myocardial infarction within 6 month study day 0 Previous receipt azacitidine , decitabine , anthracyclines , cytarabine , nucleoside analogues treatment AML MPN/MDS note cytarabine Pregnancy lactation Concurrent treatment investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>